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Abstract
Background: Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) is
currently the recommended regimen for prevention of malaria in pregnancy in endemic areas. This
study sets out to evaluate the effectiveness of IPT-SP in the prevention of maternal and placental
malaria in parturient mothers in Ibadan, Nigeria, where the risk of malaria is present all year round.
Method: During a larger study evaluating the epidemiology of congenital malaria, the effect of
malaria prophylaxis was examined in 983 parturient mothers. Five hundred and ninety eight
mothers (60.8%) received IPT-SP, 214 (21.8%) received pyrimethamine (PYR) and 171 (17.4%) did
not take any chemoprophylactic agent (NC).
Results: The prevalence of maternal parasitaemia in the IPT-SP, PYR and NC groups was 10.4%,
15.9% and 17% respectively (p = 0.021). The prevalence of placental parasitaemia was 10.5% in the
IPT-SP, 16.8% PYR and 17% NC groups, respectively (p = 0.015). The prevalence of maternal
anaemia (haematocrit <30%) was 5.7% vs. 8.9% vs. 13.4% among the IPT-SP, PYR and NC groups
respectively (p < 0.0001) while that of pre-term delivery (GA <37 weeks) was 10.5%, 19.2% and
25.3% among IPT-SP, PYR and NC groups respectively (p < 0.0001). Babies born to mothers in the
IPT-SP, PYR and NC groups had mean birth weights of 3204 ± 487.16, 3075 ± 513.24 and 3074 ±
505.92 respectively (ρ < 0.0001). There was a trend towards a lower proportion of low birth
weight babies in the IPT-SP group (p = 0.095).
Conclusion: IPT-SP is effective in preventing maternal and placental malaria as well as improving
pregnancy outcomes among parturient women in Ibadan, Nigeria. The implementation of the
recently adopted IPT-SP strategy should be pursued with vigour as it holds great promise for
reducing the burden of malaria in pregnancy in Nigeria.
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The pregnant woman runs a higher risk of contacting
malaria than her non-pregnant counterpart [1-4]. An esti-
mated 25 million pregnancies are believed to occur annu-
ally in malarious areas of sub-Saharan Africa [5]. The
transient depression of immunity to allow for develop-
ment of the allograft (foetus) is one of the reasons
adduced for the increased susceptibility of the pregnant
woman to malaria. Although malaria in pregnancy is
often asymptomatic, in the semi-immune woman, it nev-
ertheless is the cause of unfavorable pregnancy outcomes
both in the mother and in her baby [1,2,5-7]. The out-
comes of the invasion of the placenta by parasites, inflam-
matory cells and cytokines include: abortion, premature
labour, small-for-date babies and foetal/maternal death
in some instances. These unfavorable pregnancy out-
comes are associated with sequestration of malaria para-
sites in the placental intervillous spaces attached to
chondroitin-sulphate-A [8,9]. Pro-inflammatory cells and
cytokines also invade the placental bed. The net result is
impairment of foetal blood and nutrient supply, which in
turn predisposes to low birth weight (LBW). LBW, as
occurs in small-for-date babies or babies born prema-
turely, is the greatest risk factor for neonatal mortality and
a major contributor to infant mortality [9].
To prevent the adverse effects of malaria in pregnancy,
antimalarial chemoprophylaxis is generally recom-
mended. For a long time, prophylaxis with weekly
pyrimethamine or chloroquine was widely adopted in
many African countries [10]. Poor compliance and emer-
gence of drug resistant strains of Plasmodium falciparum
have, however, compromised the efficacy of these regi-
mens [11,12]. Intermittent preventive treatment (IPT)
with sulphadoxine-pyrimethamine (SP) after the first tri-
mester has been found to be effective in reducing mater-
nal anaemia, placental malaria and the incidence of LBW
in studies in eastern and southern Africa [13-17]. This
strategy involves giving a curative treatment dose of an
effective antimalarial drug at predefined intervals during
pregnancy. SP has been shown to be the most effective
single dose antimalarial drug for prevention of malaria
during pregnancy in areas where the strain of plasmo-
dium remains sensitive to it [14,15]. Studies in Kenya,
Mozambique and Malawi have shown that administra-
tion of at least two therapeutic doses of SP during the sec-
ond and third trimesters of the pregnancy at an interval of
1 month apart is most effective in HIV-negative women
[13,14,16,17]. Intermittent preventive therapy with SP
(IPT-SP) is attractive because its single dose therapy lends
itself for supervised administration in the antenatal clinic
thus ensuring compliance.
Despite the well documented lack of efficacy of pyrimeth-
amine for malaria chemoprophylaxis, many practitioners
have continued to use this approach for pregnant women
in Nigeria. This article reports the effectiveness of IPT-SP
in the prevention of maternal and placental malaria in an
urban hospital in Ibadan, Nigeria during a pilot study of
the IPT-SP strategy.
Patients and Methods
Study site and ethical issues
The study was conducted at the St Mary's Catholic Hospi-
tal Eleta Ibadan between May 2003 and October 2004. St
Mary's Hospital is a secondary health care facility run by
the Catholic mission. It is located in the heart of the
ancient city of Ibadan. However, St Mary's Hospital
attracts patients of various socio-demographic classes
from the entire city as a result of the high quality of service
it has provided over decades at reasonable cost. Ibadan is
located in the rain forest belt in south-western Nigeria.
Malaria transmission is intense year round with a peak
during the rainy season months of May to October and a
nadir during the dry season months of November to April.
In a recently conducted national efficacy study, day 14
efficacy of SP in Ibadan in acute uncomplicated malaria
was 85% [18] among children aged 6 months to five
years. The seroprevalence of HIV in the study area at the
time of the study in adults (male and female) was 2%
[19]. The University of Ibadan/University College Hospi-
tal Institutional Review Committee and the Boston Uni-
versity Institutional Review Board (collaborating
institution) provided ethical approval for the study. Writ-
ten informed consent was obtained from each study par-
ticipant or her legal guardian (mother or husband) for
those mothers less than 18 years of age.
Study subjects, enrollment and laboratory procedures
Women who participated in a larger prospective observa-
tional study evaluating the epidemiology of congenital
malaria in Ibadan, Nigeria were enrolled into the study
[20]. Only patients who had resided in the catchment area
for over two years, delivered live infants in the study hos-
pital and provided signed informed consent were enrolled
into the study. Enrolment was limited to 52 – 60 consec-
utive mother-baby pairs per month during the study
period to cover both high and low transmission seasons.
Booking clinics in St Mary's Hospital are held on Tuesdays
and Thursdays while antenatal clinics are held on Mon-
days, Wednesdays and Fridays. At the beginning of the
study, the standard operating procedure for malaria che-
moprophylaxis was weekly pyrimethamine which was
provided pre-packed for women to take at home every
Sunday. Folic acid and iron supplements were also pro-
vided for pregnant women. The importance of malaria
chemoprophylaxis and the use of haematinics (5 mg of
folic acid daily and 200 mg ferrous sulphate thrice daily)
is painstakingly explained to patients during health talksPage 2 of 8
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tal clinic visit.
Six months after commencement of the study, a pilot
study on IPT-SP was introduced in some states in Nigeria.
St Mary's Hospital was one of the hospitals selected for the
IPT-SP pilot study in Oyo state. While other centers gave
SP free to pregnant women, the study site gave IPT-SP at a
cost of 50 ($0.35) per dose for sustainability. Three tablets
of SP containing 500 mg sulphadoxine and 25 mg
pyrimethamine per tablet (Melarich™, Medreich PLC Eng-
land) were administered under supervision of midwives
at the antenatal clinic and recorded in the patients' ante-
natal case notes. The use of IPT-SP was confirmed from
the antenatal notes. Records were subsequently signed by
the midwife responsible for its administration. Enquiries
about untoward effects were made during the next clinic
visit and were recorded. An investigator assisted question-
naire was administered to enrolled mothers at delivery to
collect information on socio-demographic factors,
malaria chemoprophylaxis, and occurrence of fever and
malaria symptoms as well as anti-malaria drug use within
two weeks of delivery. Details of other clinical and labora-
tory enrollment procedures are described in the report of
the epidemiology of congenital malaria in Nigeria [20].
Babies born before 37 weeks of gestation were considered
pre-term while those born from 37 weeks of gestation and
above were considered term. Babies were weighed to the
nearest gram using an electronic weighing scale. For the
purpose of this study LBW was defined as neonatal birth
weight less than 2,500 g while a haematocrit reading of
<30% was considered as anaemia.
Chemoprophylactic drug use
For the purposes of this study, all patients were catego-
rized into three groups based on type of chemoprophylac-
tic agent used. Patients in group 1 received IPT-SP, group
2 received pyrimethamine while those who took no che-
moprophylactic agent were in group 3. Adequacy of IPT-
SP use was defined as the use of at least two therapeutic
doses of SP at least one month apart during the 2nd and 3rd
trimester of pregnancy, where second trimester is defined
as 14 to less than 28 weeks of gestation and 3rd trimester
as 28 weeks and above. Adequacy of pyrimethamine was
defined as the use of 25 mg pyrimethamine weekly two
weeks after quickening until term while the adequacy of
chloroquine was defined as the use of 300 mg (two tab-
lets) chloroquine base weekly for the same time duration
as pyrimethamine. To be considered adequately used,
proguanil needed to be taken at a dose of 200 mg daily for
the same duration as pyrimethamine and chloroquine.
Data analysis
Data collected were recorded into pre-coded case record
forms. Thereafter, the data was double entered by two
data entry clerks using EPI-INFO 6.04d (Centers for Dis-
ease Control and Prevention, Atlanta, GA, USA). Prelimi-
nary data analysis was done with EPI-INFO. Thereafter,
the data were transferred to SPSS version 10 (SPSS Inc.,
Chicago, IL, USA) for analysis. Descriptive statistics such
as means and standard deviations were used to summa-
rize quantitative variables while categorical variables were
summarized with proportions. Frequency tables and
graphs were presented for relevant variables. The student
t-test was used to compare two mean values while the one
way analysis of variance (ANOVA) was used to compare
mean values in more than two groups. The Chi-square test
was used to investigate associations between two categor-
ical variables and also to compare proportions. For signif-
icant associations, the odds ratio (OR) and 95%
confidence intervals (CI) were computed. A p-value less
than 0.05 was considered statistically significant.
Results
Over an 18 month period (May 2003 to October 2004),
983 mother-baby pairs were enrolled. The mean maternal
age was 29.6 ± 5.2 years. The youngest mother was 17 yrs
of age while the oldest was 48 yrs. Only 11 (1.1%) of the
mothers were less than 20 yrs of age. The socio-demo-
graphic characteristics of mothers in the IPT-SP, pyrimeth-
amine (PYR) and no chemoprophylactic (NC) groups
were similar (Table 1).
Pattern of anti-vector use
The vast majority (956/983; 98.4%) of study participants
admitted to using at least one form of anti-vector measure.
Mosquito screens on windows were the most commonly
used (77.9%) followed by insecticide sprays (69.1%),
coils (25%), herbs (6.6%), untreated bed nets (6.6%) and
mosquito repellants (0.5%). Insecticide treated bed nets
(ITNs) were used by only 1.1% of pregnant women partic-
ipating in the study.
Pattern of antimalarial chemoprophylactic use
Most (840/983; 85.5%) mothers admitted to using some
form of antimalarial chemoprophylaxis. The remaining
143 (14.6%) did not use any malaria chemoprophylactic
drug during the index pregnancy. More than half of the
mothers (598/983; 60.8%) received IPT-SP while 21.8%
(214/983) received pyrimethamine monotherapy. Other
chemoprophylactic agents used by mothers enrolled into
the study include chloroquine (23/983; 2.3%), herbs (4/
983; 0.4%) and proguanil (1/983; 0.1%). Five hundred
and five of 598 (84.4%) patients who received IPT-SP
received at least two therapeutic doses as stipulated in the
guideline while 94.4% (202/214) of those who took
pyrimethamine claimed to have taken adequate doses. AllPage 3 of 8
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received grossly inadequate doses of chloroquine. The
only patient who used proguanil took 100 mg daily for
less than two weeks. All the patients who took chloro-
quine, herbal preparations and proguanil were considered
as having taken no chemoprophylactic agent and were
categorized into the NC group bringing the number in
that group to 171 (17.4%).
Malaria in the two weeks before delivery
A history of febrile illness in the two weeks preceding
delivery was obtained in 9.5% (56/592), 23.5% (50/213)
and 20.4% (34/167) of the mothers who received IPT-SP,
PYR and NC respectively (p < 0.0001).
Malaria parasitaemia
At delivery, the prevalence of maternal parasitaemia was
significantly lower in the IPT-SP group when compared to
the PYR and NC groups (Table 2). Both maternal and pla-
cental malaria parasitaemia were also significantly more
prevalent among women who used pyrimethamine when
compared with those who received IPT-SP (Table 3).
There was no significant difference between the PYR and
NC groups. The differences in the prevalence of patent
parasitaemia in cord blood and in the peripheral blood of
neonates (obtained by heel stick) born to mothers in the
IPT-SP, PYR and NC groups were not statistically signifi-
cant.
Maternal and neonatal haematocrit
The mean haematocrit of parturient women who used
IPT-SP was higher than for the PYR and NC groups (p =
0.006) (Table 2). The mean haematocrit among mothers
in the IPT-SP and the NC groups was significantly differ-
ent (p= 0.002, 95% CI: -2.13 – -0.49) whereas there was
no difference between the mean haematocrit of IPT-SP
mothers and PYR mothers (p = 0.81). On the other hand,
the prevalence of maternal anaemia was lower among
IPT-SP users when compared to PYR and NC groups (ρ <
0.0001). Although there was no neonate with a haemat-
ocrit less than 30%, there was a statistically significant dif-
ference in the mean haematocrit of the three groups with
the highest haematocrit in neonates whose mothers
received IPT-SP (p = 0.041).
Birth weight and pre-term delivery
The mean birth weight of babies born to mothers who
received IPT-SP was significantly greater than those babies
born to mothers in the PYR and NC groups (p < 0. 0001)
(Table 2). When compared individually, babies born to
mothers in IPT-SP group weighed significantly more than
PYR and NC. The prevalence of LBW was found to be low-
est among mothers who received IPT-SP when compared
with mothers in the PYR and NC groups. However, these
differences were not significant (p = 0. 095). Mothers who
received IPT-SP were less likely to deliver pre-term babies
than those who did not take IPT-SP (Tables 2 and 3). Pre-
Table 1: Characteristics of parturient women who used IPT-SP, pyrimethamine or no chemoprophylactic agents
Characteristics IPT-SP Use (n = 589) Pyrimethamine (n = 214) No chemo-prophylaxis (n = 171) p-value
Age (Years)
Mean ± SD 29.6 ± 5.7 29.4 ± 4.9 30.1 ± 5.3 0.408
Range 17 – 44 18 – 43 17 – 42
Maternal Level of Education n (%)
None 13 (2.2) 3 (1.4) 4 (2.3)
Primary/Qur'anic education 74 (12.4) 31 (14.5) 26 (15.2)
Secondary school 359 (60.3) 122 (57.0) 85 (49.7) 0.307
Post 20 School 149 (25.0) 58 (27.1) 56 (32.7)
Total 595 (100) 214 (100) 171 (100)
Fathers' Level of Education n (%)
None 9 (1.5) 3 (1.4) 4 (2.5)
Primary/Qur'anic education 53 (9.0) 21 (10.1) 19 (11.7)
Secondary school 315 (53.5) 110 (53.1) 70 (43.2) 0.409
Post secondary school 212 (36) 73 (35.3) 69 (42.6)
Total 589 (100) 207 (100) 162 (100)
Gravidity n (%)
1 133 (22.2) 49 (22.9) 48 (28.2)
2 127 (21.2) 50 (23.4) 35 (20.6) 0.516
>2 338 (56.5) 115 (53.7) 87 (51.2)
Baby's Sex n (%)
Male 310 (51.8) 107 (50) 99 (57.9) 0.268Page 4 of 8
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mothers in IPT-SP, PYR and NC groups respectively (p <
0. 0001). The differences in the prevalence of preterm
delivery among IPT-SP when compared specifically to
pyrimethamine or NC groups were both statistically sig-
nificant (Table 3).
Safety evaluation
SP was well tolerated. There was no incidence of pruritus,
fixed drug eruptions or allergic reactions attributable to
any of the chemoprophylactic agents and IPT-SP used by
any of the mothers. Five mothers reported episodes of diz-
ziness within 30 minutes of taking SP. Dizziness in all
cases terminated within a few hours without any specific
treatment. There were no congenital malformations or
deaths (maternal or neonatal) among the study partici-
pants.
Discussion
Pregnancy-associated P. falciparum malaria is well recog-
nized as an important cause of morbidity leading to
maternal anaemia and LBW in the neonate [5-7,21]. The
WHO currently recommends that each pregnant woman
should receive at least two doses of IPT after quickening
[5]. This recommendation is based on reports of benefi-
cial effects of IPT-SP in preventing maternal and placental
malaria and in improving pregnancy outcome in studies
carried out in East Africa [13,14,16,17]. The findings of
this study show that IPT-SP is effective in reducing the
prevalence of maternal and placental malaria parasitae-
mia among parturient women in the urban city of Ibadan
in southwestern Nigeria, an area hyperendemic for
malaria. These findings are consistent with other reports
in East and southern African countries [13,14,16,17]
which all found IPT-SP protective against maternal and
placental malaria. The results of this study are also in
agreement with a report from Mali in West Africa which
Table 3: Risk of malaria parasitaemia and pregnancy outcomes among parturient women who received IPT-SP, pyrimethamine or no 
chemoprophylaxis in Ibadan, Nigeria
Parameter IPT-SP vs Pyrimethamine IPT-SP vs No Chemoprophylaxis
OR 95% CI p-value OR 95% CI p-value
Maternal parasitaemia 0.612 0.39–0.96 0.036 0.57 0.35 9 091 0.019
Placental parasitaemia 0.582 0.37 – 0.91 0.02 0.577 0.36 – 0.93 0.022
Maternal anemia (Haematocrit <30%) 1.62 0.91 – 2.92 0.11 3.008 1.74 – 5.19 <0.0001
Pre-term delivery (GA <37 weeks) 2.03 1.31 – 3.31 0.002 2.88 1.84 – 4.35 <0.0001
Table 2: Effects of IPT-SP, pyrimethamine or no chemoprophylactic agent on malaria parasitaemia and pregnancy outcomes in 
parturient women in southwestern Nigeria
Outcome measure IPT-SP Pyrimethamine No Chemoprophylaxis P value
N = 598 N = 214 N = 171
n (%) n (%) n (%)
Maternal parasitemia 62 (10.4%) 34 (15.9) 29 (17.0) 0.021
Placental parasitemia 63 (10.5%) 36 (16.8) 29 (17.0) 0.015
Cord parasitemia 16 (2.7%) 9 (4.2) 9 (5.3) 0.210
Neonatal parasitemia 4 (0.7%) 3 (1.4) 1 (0.6) 0.553
Maternal haematocrit (%)
Mean ± SD 36.48 ± 4.55 36. 39 ± 4.7 35.17 ± 5.58 0.006
Range 18 – 45 20 – 45 17 – 45
Maternal anaemia
(Haematocrit <30%) 33/579 (5.7%) 19 (8.9) 26 (15.4) <0.0001
Pre-term delivery 
(Gestational age <37 weeks) 63 (10.5%) 41 (19.2) 43 (25.3) <0.0001
Neonatal birth weight(gm)
Mean ± SD 3204.3 ± 487.2 3075.7 ± 513.24 3074.7 ± 505.9 <0.0001
Range 1500 – 4700 1300 – 4500 1400 – 4500
Low birth weight (%) 31/595 (5.2) 17 (7.9) 16 (9.4) 0.095
Neonatal haematocrit (%)
Mean ± SD 58.2 ± 7.8 57.1 ± 7.66 56.8 ± 8.0 0.041
Range 35 – 79 34 – 75 31 – 75
Placental weight (gm)
Mean 605.54 ± SD 605.5 ± 113.6 607.7 ± 131.9 588.9 ± 136. 0.253Page 5 of 8
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maternal and placental malaria [22]. All of the aforemen-
tioned studies in other parts of Africa were randomized,
controlled trials, whereas this study used an observational
prospective design. Despite this major limitation, IPT-SP
was highly effective in reducing maternal and newborn
complications of malaria in pregnancy.
Challis et al [17] working in Mozambique reported a con-
sistent reduction in the prevalence of malaria throughout
pregnancy among mothers and also in the prevalence of
placental malaria at parturition similar to the findings of
the present study. Unlike the observation on maternal and
placental malaria, the use or non-use of IPT-SP did not
affect the prevalence of cord or neonatal malaria. Roger-
son et al (2000) had earlier reported similar findings from
Malawi. The incidence of cord and neonatal malaria was
low with a cord parasite rate of 3.5% and congenital
malaria rate of 0.8% in the study being reported here. In
contrast to these findings, Challis et al [17] in their report
noted a significant reduction in the incidence of congeni-
tal malaria among the neonates whose mothers used IPT-
SP compared with placebo. Unlike the report of Challis et
al there was no difference in the incidence of congenital
malaria among babies born to mothers who received IPT-
SP, PYR and NC. This may be due to the already low inci-
dence of congenital malaria in the current study.
The differences in the prevalence of maternal and placen-
tal malaria among IPT-SP users and non-users occurred
despite the fact that the vast majority of parturient women
used one anti-vector measure or another. The pattern of
anti-vector use was similar in both groups to a large
extent. Although ITNs have been shown to be effective in
the control of malaria in pregnant women [23,24], its use
among pregnant women in the study area was very low
(1.1%). The women who used no chemoprophylactic
agent through out pregnancy consisted largely of patients
who did not receive antenatal care at the study hospital
and those who booked very late during the index preg-
nancy. Patients who used chloroquine, herbs, and pro-
guanil were grouped into the same group as those who
used no chemoprophylaxis because of poor compliance
with these prophylactic agents. Resistance to chloroquine
is also well established in the study area and many parts
of sub-Saharan Africa [5,12,22]. The results of this study,
which showed significant differences between IPT-SP and
pyrimethamine users, provides further confirmation of
the earlier reported compromised efficacy of pyrimeth-
amine in preventing malaria in pregnancy [11]. The use of
IPT-SP is clearly superior to pyrimethamine in protecting
pregnant women from peripheral and placental parasitae-
mia, maternal anaemia and their neonates from LBW.
Judging from the marked reduction in the incidence of
clinically diagnosed malaria in the two weeks preceding
delivery in our study, IPT-SP use significantly reduced epi-
sodes of febrile illnesses suspected to be malaria during
the last two weeks of pregnancy compared to mothers
who used pyrimethamine or no chemoprophylaxis.
Although it would have been useful to evaluate the timing
of the last dose of IPT-SP prior to delivery, these data were
not captured in the database of the study reported here.
Effect of IPT-SP on LBW
LBW and prematurity are the greatest risk factors for neo-
natal mortality and a major contribution to infant mortal-
ity [7,9]. In this study, babies born to mothers who
received IPT-SP on the average weighed more than babies
born to those who used pyrimethamine and no chemo-
prophylactic agent respectively. There was also a trend
towards a lower prevalence of LBW in the IPT-SP group. In
addition, the prevalence of preterm delivery was also sig-
nificantly lower among IPT-SP users when compared with
those who took pyrimethamine.
Effect of IPT-SP use on prevalence of maternal and 
neonatal anaemia
Anaemia is a well recognized consequence of malaria.
Although maternal anaemia is multifactorial, malaria is
known to contribute significantly to its occurrence in
pregnancy. The prevalence of anaemia was least among
parturient women who received IPT-SP during pregnancy
when compared with the PYR and NC groups. Anaemia
was earlier reported by workers in the same environment
to have a negative impact on pregnancy outcome with still
births occurring more often in anemic mothers [25]. Aim-
aku and Olayemi [25] also found that the birth weight
and Apgar scores were significantly higher with increasing
maternal haematocrit. The beneficial effect of IPT-SP on
reduction of the prevalence of maternal anaemia is a wel-
comed finding which would lead to improved favorable
pregnancy outcomes. The findings of this study are similar
to another report from West Africa where IPT-SP was
found to be protective against maternal anaemia, placen-
tal parasitaemia and LBW [22]. Unlike the Mali study
however, the prevalence of maternal and placental
malaria was much lower in our study. A prevalence of
maternal and placental parasitaemia of 10.4% and 10.5%
was recorded among IPT-SP users in our study compared
to 21.8% and 24.5% in Mali. The Mali study was carried
out in semi rural towns of Baudigana and Koro while the
current study being reported was carried out in the urban
city of Ibadan. Malaria transmission is more intense in
rural than urban areas [26]. In addition, malaria transmis-
sion is perennial in Ibadan while it is seasonal in Bandia-
gana and Koro which might translate to lower acquired
immunity among Malian women. Although the presence
of malaria parasites in the placenta is a useful marker ofPage 6 of 8
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pregnancy, these findings are another reminder that meas-
urement of impact indicators gives the best picture of effi-
cacy and effectiveness. No baby in the study had a
haematocrit below 31% and there was no significant dif-
ference between the mean haematocrit of babies born to
mothers who received IPT-SP, pyrimethamine or the
entire population of non IPT-SP users
Safety and efficacy issues
Adverse events reported by study participants on IPT-SP
and other chemoprophylactic agents were mild and did
not necessitate any treatment. This is similar to the find-
ings of previous workers [16,17,22]. Serious life-threaten-
ing allergic reactions to SP have also been reported to be
relatively rare [27]. Concomitant administration of high
dose folate supplementation (5 mg daily) as was done in
St Mary's Hospital Eleta, the study site, was recently
reported to compromise the efficacy of SP in a well
designed clinical trial in Kenya [28]. It may be important
to avoid high dose in favour of low dose (0.4 mg daily)
folate supplementation in pregnant women receiving IPT-
SP pending further elucidation of this drug-drug interac-
tion.
Conclusion
IPT-SP is highly effective in preventing maternal and pla-
cental malaria among parturient women in Ibadan, south-
western Nigeria as well as in improving pregnancy
outcomes, including a lower prevalence of pre-term deliv-
eries, bigger babies and lower prevalence of maternal
anaemia. This study has once again confirmed the lack of
efficacy of pyrimethamine for the prevention of maternal
and placental malaria in pregnant Nigerian women [11].
The National Malaria Control Division of the Federal
Ministry of Health recently adopted the policy of IPT-SP as
part of the malaria control strategy in Nigeria [29]. The
implementation of the recently adopted IPT-SP strategy if
pursued with vigour holds great promise in reducing the
burden of malaria in pregnancy in the country especially
if combined with widespread use of insecticide-treated
bed net among pregnant women.
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